India’s cancer care system is facing a growing challenge as shortages of two essential chemotherapy drugs Cisplatin and Carboplatin continue to impact treatment schedules at hospitals across the country. The shortage is forcing oncologists to make difficult decisions, including delaying treatments, adjusting dosages, and turning to more expensive alternatives that may not offer the same level of effectiveness.
Why These Drugs Are So Important
Cisplatin and carboplatin are among the most widely used chemotherapy medications in cancer treatment. They serve as the foundation of treatment protocols for several major cancers, including lung, ovarian, head and neck, and gastrointestinal cancers.
For many patients, these drugs remain the standard first-line treatment, and there are limited direct substitutes that can deliver comparable results.
What’s Causing the Shortage?
Experts say the issue goes beyond a simple supply disruption. The shortage is linked to a combination of factors, including global supply-chain constraints, rising raw material costs, manufacturing economics, and production challenges affecting oncology drugs worldwide.
The situation has exposed vulnerabilities in the cancer drug supply chain, making access to critical medicines increasingly difficult for hospitals and healthcare providers.
Hospitals Are Feeling the Pressure
Cancer centres across India are reporting treatment disruptions as procurement teams struggle to secure adequate stock.
Doctors say chemotherapy schedules are being postponed, doses are being optimized to stretch available supplies, and inventory levels are being monitored more closely than ever before. In some cases, hospitals are coordinating with one another to share available stocks and ensure that the most urgent patients continue receiving treatment.
Oncologists Face Difficult Choices
The shortage has created ethical and clinical dilemmas for doctors who must decide how to allocate limited supplies.
Many oncologists are being forced to prioritize patients receiving potentially curative treatment while considering alternative therapies for others. Such decisions can be emotionally and professionally challenging, particularly when treatment outcomes may be affected.
Alternatives Come at a Cost
When cisplatin or carboplatin are unavailable, doctors often have no choice but to switch patients to alternative chemotherapy regimens.
However, specialists warn that these alternatives are frequently more expensive and may not achieve the same clinical outcomes. This not only increases the financial burden on patients but also raises concerns about long-term treatment effectiveness.
A Recurring Healthcare Challenge
Several cancer specialists have described the shortage as an ongoing structural problem rather than a temporary disruption. Healthcare providers are calling for stronger planning, improved manufacturing capacity, and better coordination across the pharmaceutical supply chain to prevent similar crises in the future.
Measures Being Taken
Leading oncology centres have already implemented emergency strategies, including:
- Enhanced inventory monitoring
- Inter-hospital drug sharing
- Prioritisation of curative cancer cases
- Dose optimisation protocols
- Alternative treatment planning where necessary
These measures are helping manage the immediate crisis, but experts caution that long-term solutions are urgently needed.
Impact on Patients
For cancer patients and their families, treatment delays can create significant anxiety and uncertainty. Many patients depend on carefully timed chemotherapy schedules, and disruptions may affect treatment outcomes.
Doctors continue to emphasize that patients should remain in close contact with their oncology teams and discuss any concerns regarding medication availability and treatment planning.
Calls for Long-Term Solutions
Medical experts are urging policymakers, pharmaceutical manufacturers, and healthcare institutions to work together to strengthen India’s oncology drug supply network. Ensuring a stable supply of essential chemotherapy medicines remains critical as cancer cases continue to rise across the country.
While hospitals are working to minimize disruptions, oncologists warn that resolving the shortage quickly is essential to prevent further strain on patients and the healthcare system.